Briacell Therap (NASDAQ:BCTX – Get Free Report) and Exact Sciences (NASDAQ:EXAS – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.
Valuation & Earnings
This table compares Briacell Therap and Exact Sciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Briacell Therap | N/A | N/A | -$26.31 million | ($44.05) | -0.10 |
| Exact Sciences | $2.76 billion | 7.08 | -$1.03 billion | ($5.32) | -19.23 |
Institutional and Insider Ownership
15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 88.8% of Exact Sciences shares are held by institutional investors. 5.7% of Briacell Therap shares are held by insiders. Comparatively, 1.2% of Exact Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent recommendations for Briacell Therap and Exact Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Briacell Therap | 1 | 0 | 1 | 0 | 2.00 |
| Exact Sciences | 1 | 20 | 2 | 1 | 2.13 |
Briacell Therap presently has a consensus target price of $320.00, indicating a potential upside of 7,324.59%. Exact Sciences has a consensus target price of $89.56, indicating a potential downside of 12.46%. Given Briacell Therap’s higher possible upside, research analysts clearly believe Briacell Therap is more favorable than Exact Sciences.
Risk and Volatility
Briacell Therap has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.
Profitability
This table compares Briacell Therap and Exact Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Briacell Therap | N/A | -275.07% | -188.44% |
| Exact Sciences | -32.01% | 1.67% | 0.70% |
Summary
Exact Sciences beats Briacell Therap on 9 of the 14 factors compared between the two stocks.
About Briacell Therap
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
About Exact Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company’s pipeline products focus on enhancing the Cologuard test’s performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Receive News & Ratings for Briacell Therap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Briacell Therap and related companies with MarketBeat.com's FREE daily email newsletter.
